Explore why therapeutic inertia keeps plaque psoriasis patients cycling through topicals instead of escalating to systemic therapy.
Back
Evolving Approaches to Plaque Psoriasis Management
A Peers & Perspectives video series in which Andrew Mastro, MS, PA-C, and Alexa Hetzel, MS, PA-C, examine the evolving oral and injectable treatment landscape in plaque psoriasis, from therapeutic inertia and topical cycling to the efficacy, safety, and durability of icotrokinra alongside TYK2 inhibitors, PDE4 inhibitors, and injectable biologics.
Evolving Approaches to Plaque Psoriasis Management
Episodes
All
All
Trace how oral plaque psoriasis therapy has evolved over time, from PDE4 and TYK2 inhibition to once-daily oral peptides.
Advertisement
Advertisement
Trending on HCPLive
1
Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial
2
What the ADorable-1 Trial Means for Pediatric Eczema Care
3
MV130 Mucosal Vaccine Reduces COPD Exacerbations in Phase 3 Trial
4
ADorable-1 Results: Key Findings in Pediatric Atopic Dermatitis
5